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The paper by Liew et al. in this issue of the Journal
confirms other observations on the consequences of
switching from branded to generic statins [1]. The com-
mon pattern observed is that the staggering costs of lipid-
lowering therapy lead to national guidelines and policies
that recommend or even dictate switching to generic prep-
arations. This is associated, on average, with a reduction
in pharmacological potency and an increase in low-density
lipoprotein (LDL) plasma levels. The net effect is a re-
duction in costs that comes with a loss of preventive
efficacy. However, this is not an inevitable consequence
of these policies. Most include the possibility to switch
back to branded statins if treatment targets are not reached
with generic variants.
The proportion of the observed effects is obviously de-
pendent on the population, the drugs involved and the
methods and assumptions that were selected for the analysis.
It is important to note that the calculations are generally
based on published observations of cardiovascular event
rates during 5 or 10 year follow-up [2]. The impact on
lifetime risk may be significantly greater, both in relative
and absolute event rates [3].
For a balanced view on the consequences of these
observations, it may be appropriate to distinguish pri-
mary from secondary prevention since the effects of
switching are likely greater in secondary prevention,
where absolute risks of cardiovascular events are generally
greater. This distinction could not be made in the pres-
ent study on pharmacy data. Similarly, no data are
available on the selection patterns that led to the 15%
of all statin users in whom a switch was apparently
considered appropriate by their physician. Potentially,
this could have occurred more frequently in lower risk
patients or in those who had LDL levels well below the
recommended target plasma LDL level (2.5 mmol/l). In
this case, the impact of switching may be smaller than
was now calculated.
Irrespective of the average impact on a population,
physicians who follow these guidelines need to carefully
consider the consequences for their individual patient. If
a decision is made to switch to a generic preparation,
the new agent and its dose should at least be equivalent
to the drug that is stopped and the LDL plasma level
should be checked against previous values and against
guideline-recommended target levels.
Interestingly, the Pfizer patent on atorvastatin has now
expired in Europe and as of 19 March 2012, generic ator-
vastatin has been admitted to the Dutch market. It is avail-
able from Ranbaxy and from Pfizer. It remains to be
established how many patients will now be switched back
to atorvastatin.
Important as these observations are for lipid-lowering
therapy, they signal a development that may have conse-
quences far beyond cardiovascular prevention. Written
primarily with the intention to improve the quality of care,
guidelines in medicine are increasingly used as a basis for
legal, financial and licensing policies. The 2006 Dutch
guideline on Cardiovascular Risk Management is a good
example, where professional recommendations formed the
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therapy. This step reduced physicians’ freedom to select drug
therapy and in fact reduced professional autonomy. The sub-
sequent reductions in preventive therapy, as described in the
paper byLiewetal.,represent a serious,unintendedsideeffect
of the guideline [1].
This ‘external’ use of our guidelines has important
consequences for professional societies that issue guide-
lines. External use should be routinely anticipated. This
requires explicit attention at multiple levels, ranging
from the selection of members for the guideline work-
ing group to the wording of the final document. At
each level, an inherent conflict needs to be resolved
between the responsibility of a physician for the individ-
ual patient and our collective responsibility for affordable
health care.
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